COMPOSITIONS FOR PREVENTION OR TREATMENT OF ANOREXIA-CACHEXIA SYNDROME AND USES THEREOF

• US 20110028542A1
• Filed: 05/06/2008
• Published: 02/03/2011
• Est. Priority Date: 05/31/2007
• Status: Abandoned Application

• Current Assignee: F.P.L. Pharma Inc. (Applitox Bio Pharma, Inc.)
• Original Assignee: Andre Pichette, Jean Legault
• Inventors: Legault, Jean, Pichette, Andre
• Application Number:
  US12/602,406
• Publication Number:
  US 20110028542A1
• Time in Patent Office: Days
• US Class Current: 514/458
• CPC Class Codes: A61K 31/015 carbocyclic
• CPC Class Codes: A61K 31/337 having four-membered rings, e.g. taxol
• CPC Class Codes: A61P 19/00 Drugs for skeletal disorders
• CPC Class Codes: A61P 21/00 Drugs for disorders of the muscular or neuromuscular system
• CPC Class Codes: A61P 3/00 Drugs for disorders of the metabolism of the blood or the extracellular fluid A61P7/00
• CPC Class Codes: A61P 35/00 Antineoplastic agents

Abstract

A pharmaceutical composition for 1) increasing weight gain; and/or 2) decreasing weight loss; and/or 3) increasing appetite in a subject in need thereof, comprising purified β-caryophyllene together with a pharmaceutically acceptable carrier. Also provided are pharmaceutical compositions for use in the prevention or treatment of Anorexia-Cachexia Syndrome, the pharmaceutical composition comprising purified β-caryophyllene together with a pharmaceutically acceptable carrier.

Claims

1. (canceled)

2. A pharmaceutical composition for use in the prevention or treatment of Anorexia-Cachexia Syndrome, the pharmaceutical composition comprising purified β

-caryophyllene together with a pharmaceutically acceptable carrier.

5. The composition of claim 2, wherein the Anorexia-Cachexia Syndrome is Cancer Anorexia-Cachexia Syndrome.

8. The composition of claim 2, wherein the Anorexia-Cachexia Syndrome comprises in addition to involuntary progressive weight loss, one or more of:

a) progressive loss of both fat and skeletal muscle,

b) refractoriness of weight loss to increased nutritional input,

c) elevated resting energy expenditure (REE),

d) decreased protein synthesis,

e) altered carbohydrate metabolism,

f) hyper-catabolism of muscle via the ATP-ubiquitin-proteasome pathway of proteolyis;

g) increased degradation of adipose tissue via lipolysis;

h) asthenia;

i) anemia,

j) chronic fatigue;

k) nausea; and

l) loss of bone mass.

9. The composition of claim 8, wherein the β

-caryophyllene is substantially pure β

-caryophyllene.

12. The composition of claim 9, wherein the composition further comprises one or more solubilizers selected from the group consisting of a PEG400, a derivative of castor oil and ethylene oxide, and polysorbate.

13. The composition of claim 12, wherein the composition further comprises one or more antioxidants selected from the group consisting of vitamin E, a hydrophilic vitamin E analog, alpha tocopherol acetate, butylated hydroxytoluene (BHT) and butylated hydroxyanisole (BHA).

14. The composition of claim 13, wherein the one or more antioxidants is 6-Hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid.

15. The composition of claim 13, wherein the one or more antioxidants is vitamin E.

3-4. -4. (canceled)

6-7. -7. (canceled)

10-11. -11. (canceled)

16-42. -42. (canceled)

43. A method of 1) increasing weight gain;

and/or

     2) decreasing weight loss; and

/or

     3) increasing appetite in a subject in need thereof comprising administering to the subject an effective amount of a pharmaceutical composition comprising purified β

-caryophyllene together with a suitable pharmaceutical carrier, whereby the subject experiences an increased weight gain; and

/or a decreased weight loss; and

/or an increased appetite.

47. The method of claim 43, wherein the subject suffers from Cancer Anorexia-Cachexia Syndrome.

50. The method of claim 43, wherein the subject suffers from Anorexia-Cachexia Syndrome and wherein said Anorexia-Cachexia Syndrome comprises in addition to involuntary progressive weight loss, one or more of:

a) progressive loss of both fat and skeletal muscle,

b) refractoriness of weight loss to increased nutritional input,

c) elevated resting energy expenditure (REE),

d) decreased protein synthesis,

e) altered carbohydrate metabolism,

f) hyper-catabolism of muscle via the ATP-ubiquitin-proteasome pathway of proteolyis;

g) increased degradation of adipose tissue via lipolysis;

h) asthenia;

i) anemia,

j) chronic fatigue;

k) nausea; and

l) loss of bone mass.

51. The method of claim 50, wherein the β

-caryophyllene is substantially pure β

-caryophyllene.

54. The method of claim 50, wherein the composition is administered in combination with an antitumoral agent.

63. The method of claim 50, wherein the subject in need thereof is a subject which has lost more than 5% of his or her weight as compared to his or her weight prior to the onset of said Anorexia-Cachexia Syndrome.

64. The method of claim 50, wherein the subject in need thereof is a subject which has lost at least 10% of his or her weight as compared to his or her weight prior to the onset of said Anorexia-Cachexia Syndrome.

67. The method of claim 51, wherein the composition further comprises one or more solubilizers selected from the group consisting of a PEG400, a derivative of castor oil and ethylene oxide, and polysorbate and one or more antioxidants selected from the group consisting of vitamin E, a hydrophilic vitamin E analog, alpha tocopherol acetate, butylated hydroxytoluene (BHT) and butylated hydroxyanisole (BHA).

68. The method of claim 67, wherein the one or more antioxidants is 6-Hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid.

69. The method of claim 67, wherein the one or more antioxidants is vitamin E.

72. The method of claim 67, wherein the one or more solubilizers is a derivative of castor oil and ethylene oxide.

44. A method of treating or preventing Anorexia-Cachexia Syndrome (ACS) comprising administering to a subject in need thereof a therapeutically effective amount of a composition comprising purified β

-caryophyllene together with a suitable pharmaceutical carrier, whereby ACS is treated or prevented.

45-46. -46. (canceled)

48-49. -49. (canceled)

52-53. -53. (canceled)

55-62. -62. (canceled)

65-66. -66. (canceled)

70-71. -71. (canceled)

73-81. -81. (canceled)